Source:http://linkedlifedata.com/resource/pubmed/id/12841875
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
2003-7-4
|
pubmed:abstractText |
Allogeneic bone marrow transplantation and donor lymphocyte infusion are powerful treatments for chemotherapy-resistant leukemia. Tumor eradication is attributed to a graft-versus-leukemia reaction by the donor-derived cytotoxic T lymphocytes (CTLs), but the same cell population may cause severe graft-versus-host disease. One strategy to suppress harmful CTL activity is to incorporate a suicide gene into the donor lymphocytes prior to infusion, and to destroy these cells when they aggressively attack nonmalignant host tissues. In this study, we investigated the feasibility of using a Fas-estrogen receptor fusion protein (MfasER) to control T cell-mediated cytotoxicity, based on our previous finding that the chimera transmits a Fas-mediated death signal through activation by estrogen binding. A murine CTL line CTLL-2 was transfected with a vector encoding MfasER, and the growth, viability and cytotoxic activity of the transfected cells (CTLL/MfasER) were analyzed. The expression of apoptosis-related proteins such as Fas ligand and perforin was also investigated. In the absence of estrogen, CTLL/MfasER showed similar growth to parental CTLL-2, and the killing activity was preserved. Addition of 10 (-7) M estrogen induced a rapid apoptosis of CTLL/MfasER, and the cytotoxicity was severely impaired. A decrease of Fas ligand and perforin in the estrogen-treated CTLL/MfasER was seen in an immunoblot analysis. These functional and biochemical analyses showed that the estrogen-inducible apoptosis in MfasER-expressing CTLs rapidly terminated their target cell killing. The feasibility of using the MfasER-estrogen system to control graft-versus-host disease was demonstrated.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1347-9032
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
94
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
639-43
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12841875-Animals,
pubmed-meshheading:12841875-Antigens, CD95,
pubmed-meshheading:12841875-Apoptosis,
pubmed-meshheading:12841875-Base Sequence,
pubmed-meshheading:12841875-Cell Division,
pubmed-meshheading:12841875-Cell Survival,
pubmed-meshheading:12841875-Cytotoxicity, Immunologic,
pubmed-meshheading:12841875-DNA Primers,
pubmed-meshheading:12841875-Kinetics,
pubmed-meshheading:12841875-Mice,
pubmed-meshheading:12841875-Receptors, Estrogen,
pubmed-meshheading:12841875-Recombinant Fusion Proteins,
pubmed-meshheading:12841875-T-Lymphocytes, Cytotoxic
|
pubmed:year |
2003
|
pubmed:articleTitle |
Reduction of CTLL-2 cytotoxicity by induction of apoptosis with a Fas-estrogen receptor chimera.
|
pubmed:affiliation |
Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical School, Tochigi 329-0498, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|